FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a conjugate of an anti-hB7-H3 antibody and a drug for inhibiting Bcl-xL (options). In one of implementations, the antibody is IgG1 antibody against hB7-H3, containing a variable region of a heavy chain, containing CDR3 domain of the heavy chain, containing an amino acid sequence SEQ ID NO:35, CDR2 domain of the heavy chain, containing an amino acid sequence SEQ ID NO:34, and CDR1 domain of the heavy chain, containing an amino acid sequence SEQ ID NO:33; and a variable region of a light chain containing CDR3 domain of the light chain, containing an amino acid sequence SEQ ID NO:39, CDR2 domain of the light chain, containing an amino acid sequence SEQ ID NO:38, and CDR1 domain of the light chain, containing an amino acid sequence SEQ ID NO:37.
EFFECT: invention expands the arsenal of means for inhibiting Bcl-xL.
3 cl, 5 dwg, 29 tbl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2776489C2 |
CONJUGATE ANTIBODY-DERIVATIVE OF PYRROLOBENZODIAZEPINE | 2018 |
|
RU2820928C2 |
ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
ANTIBODIES TO TICAGRELOR AND APPLICATION METHODS | 2015 |
|
RU2754468C2 |
ANTIBODY TO B7H3-EXATECAN ANALOGUE CONJUGATE AND ITS USE IN MEDICINE | 2019 |
|
RU2785664C2 |
ANTIBODY AND DRUG CONJUGATES FOR DESTRUCTION OF HEMATOPOIETIC STEM CELLS | 2017 |
|
RU2781444C2 |
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
ANTI-FcRH5 ANTIBODIES | 2014 |
|
RU2687132C2 |
Authors
Dates
2022-01-19—Published
2017-06-07—Filed